NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
Clinical Trials
10 trialsNCT06540326 2025-12-22
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06764680 2025-08-24
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07061210 2025-07-11
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT07044921 2025-07-01
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
Chinese PLA General Hospital
Phase 2 Recruiting
NCT04730544 2025-06-13
NIPISAFE
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Active not recruiting
NCT07007767 2025-06-06
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT05727163 2025-05-30
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sun Yat-sen University
Phase 2 Recruiting
NCT06973343 2025-05-15
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
Anhui Provincial Cancer Hospital
Phase 2 Not yet recruiting
NCT06959589 2025-05-06
The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting